Xiuzheng Pharmaceutical Group Co signed an agreement to establish its East China R&D and Manufacturing Center in Jiangyan district, Taizhou, on Feb 20, marking a new milestone for the city's healthcare industry. The project, with a total investment of 5 billion yuan ($690.86 million), will serve as a hub for research innovation, industrial incubation, and green production.
Xiuzheng Pharmaceutical Group Co signs an agreement to establish its East China R&D and Manufacturing Center in Jiangyan district, Taizhou on Feb 20. [Photo/WeChat account: jyrmzf]
The first phase of the project will focus on the establishment of a biopharmaceutical research institute dedicated to biomedical research, the development of cell technology, product testing, and experimental studies. The second phase will include a biopharmaceutical and medical device manufacturing center.
Jiangyan is committed to creating a top-tier business environment and accelerating the implementation of projects, working with Xiuzheng Pharmaceutical Group to build a leading biopharmaceutical innovation hub in the Yangtze River Delta region.